LIVE
Ambience Healthcare Expands Clinical AI Suite for Hospital Operations AI Models Vulnerable to Manipulation in Simulated Warfare Scenarios, Research Shows AWS Highlights Enterprise Governance and AI Workspace Quick Ahead of re:Invent 2026 LoanPro Integrates Amazon Bedrock to Automate Loan Servicing Workflows Google Brings Wallet App to iOS Users Across the United States Microsoft Reveals Cause of Global Outlook Outage AWS Outlines Phased Roadmap for Responsible Agentic AI Governance Google updates Gemini settings to separate chat history from AI model training Uber Eats and Zipline launch autonomous drone food delivery in Houston Google Prepares 'Fast Switch' Feature to Bring iPhone-Style eSIM Transfer to Android Ambience Healthcare Expands Clinical AI Suite for Hospital Operations AI Models Vulnerable to Manipulation in Simulated Warfare Scenarios, Research Shows AWS Highlights Enterprise Governance and AI Workspace Quick Ahead of re:Invent 2026 LoanPro Integrates Amazon Bedrock to Automate Loan Servicing Workflows Google Brings Wallet App to iOS Users Across the United States Microsoft Reveals Cause of Global Outlook Outage AWS Outlines Phased Roadmap for Responsible Agentic AI Governance Google updates Gemini settings to separate chat history from AI model training Uber Eats and Zipline launch autonomous drone food delivery in Houston Google Prepares 'Fast Switch' Feature to Bring iPhone-Style eSIM Transfer to Android

Alphabet's Isomorphic Labs Secures $5 Billion for AI Drug Discovery Platform

🤖 AI Models 2 min read 👁 8

Alphabet's drug discovery spinout Isomorphic Labs has secured $5 billion in a Series C funding round to accelerate clinical trials and expand its AI platform.

Alphabet's Isomorphic Labs Secures $5 Billion for AI Drug Discovery Platform🤖AI Models

Photo: thenextweb.com

Key points

  • Isomorphic Labs raised $5 billion in a Series C funding round co-led by Sequoia Capital and Greenoaks.
  • The capital will accelerate clinical trials and expand drug design capabilities into large-molecule biologics.
  • The company maintains active partnerships with major pharmaceutical firms including Eli Lilly, Novartis, and Johnson & Johnson.

Isomorphic Labs, an Alphabet-backed drug discovery enterprise led by Demis Hassabis, announced a $5 billion Series C funding round co-led by Sequoia Capital and Greenoaks. The fresh capital arrives just six months after the firm secured a $2.1 billion investment in May, with additional participation from Andreessen Horowitz and continued backing from Alphabet alongside existing backers like Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.

While the company did not officially reveal its corporate valuation, recent financial reports suggest the round values the enterprise at approximately $50 billion. Hassabis stated that the proceeds will primarily accelerate the firm's transition into clinical trials, with the ultimate objective of developing a platform capable of engineering hundreds of pharmaceutical candidates annually. The organization currently manages over 20 active pipelines spanning oncology and immunology, including collaborative projects with major drugmakers such as Eli Lilly, Novartis, and Johnson & Johnson.

Building upon the foundational success of Google DeepMind's AlphaFold protein structure model, Isomorphic plans to scale its proprietary IsoDDE drug design engine beyond conventional small-molecule therapeutics into diverse biological modalities, including large-molecule biologics. Although no regulatory body has yet approved an entirely AI-engineered medicine, Hassabis confirmed that the company remains on schedule with its regulatory submissions and development milestones.

What to watch next: Monitor the progression of Isomorphic's upcoming regulatory filings as the company moves toward its anticipated clinical trial phase.

Source thenextweb.com — thenextweb.com/news/isomorphic-labs-5bn-series-c-sequoia-greenoaks ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.